Moderna, Inc. (MRNA)
Moderna's AI Could Get a Hantavirus Vaccine Here Faster
Drug development has always been a slow business. A single medicine can take 10 to 15 years and cost billions before it reaches a patient.
Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging.
Moderna's stock is rallying on hopes it could develop a hantavirus vaccine.
Here's how much Moderna's stock has rallied off renewed focus on hantavirus research
The public is growing increasingly concerned about the possibility that a hantavirus outbreak on a cruise could spark a new pandemic.
Moderna shares extend gains as hantavirus vaccine work draws attention
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) shares continued to extend recent gains on Monday as investors welcomed reports that the company is researching a hantavirus vaccine and advancing early-stage work in the area. Shares of Moderna have added more than 16% in the last five days, trading hands at about $55.
Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday's close of $54.35.
Moderna stock soars as hantavirus fears spark outbreak trade
Moderna shares surged on Monday as investors rushed into vaccine and biotech stocks following reports of a hantavirus outbreak linked to a cruise ship, despite health authorities maintaining that the overall public health risk remains low. The stock rose 9.43% to $59.48, its intraday high after a US national tested mildly positive for the Andes strain of hantavirus.
Moderna Stock Jumps. U.S. Passenger on Hantavirus Cruise Ship Tests Positive.
The U.S. health department said one passenger on a repatriation flight has tested mildly positive for the virus, while another is currently experiencing mild symptoms.
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales
MRNA narrows Q1 loss and beats revenue estimates as international vaccine sales surge, lifting shares despite hefty litigation charges.
Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported first quarter 2026 revenue that came in well above Wall Street expectations, but posted a wider-than-expected net loss and missed earnings estimates due in part to a significant one-time litigation settlement charge. The biotech company generated revenue of $389 million for the quarter, compared with consensus estimates of about $251.8 million.
Moderna Q1 Earnings: Revenue Beat Overshadowed By Litigation Charge, Pipeline Drives Outlook
Moderna (MRNA) delivered a strong 1Q26 revenue beat, driven by international COVID-19 vaccine sales, and reaffirmed 2026 guidance for up to 10% revenue growth. Cost discipline is improving, with R&D and SG&A expenses down meaningfully, but a $0.9B litigation charge led to a wider net loss and negative gross margins. Pipeline momentum is central, with key regulatory catalysts ahead—especially the mRNA-1010 flu vaccine (FDA PDUFA August 5) and oncology assets in late-stage trials.
Moderna (MRNA) Reports Q1 Loss, Beats Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $3.02. This compares to a loss of $2.52 per share a year ago.
Moderna Reports Higher Revenue but Posts a Loss
Moderna reported an increase in revenue during the first quarter, citing higher Covid-19 vaccine sales in international markets.
